Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8391)
All Articles published online
|
Publishing Process of This Article
|
Jun 21, 2020 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Herat LY, Ward NC, Magno AL, Rakoczy EP, Kiuchi MG, Schlaich MP, Matthews VB. Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. World J Gastroenterol 2020; 26(23): 3225-3235 [PMID: 32684737 DOI: 10.3748/wjg.v26.i23.3225] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i23/3225.htm |
| Number | Citing Articles |
| 1 |
Jennifer R. Matthews, Lakshini Y. Herat, Aaron L. Magno, Shelley Gorman, Markus P. Schlaich, Vance B. Matthews. SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging. Biomedicines 2020; 8(11): 514 doi: 10.3390/biomedicines8110514
|
| 2 |
Aaron L. Magno, Lakshini Y. Herat, Márcio G. Kiuchi, Markus P. Schlaich, Natalie C. Ward, Vance B. Matthews. The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α. Journal of Clinical Medicine 2020; 9(9): 2764 doi: 10.3390/jcm9092764
|
| 3 |
Qiong Yang, Ling Deng, Changmei Feng, Jianghua Wen. Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice. PeerJ 2024; 12: e17055 doi: 10.7717/peerj.17055
|
| 4 |
Yanxia Chen, Mian Wang. New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes. Drug Design, Development and Therapy 2021; : 4849 doi: 10.2147/DDDT.S334325
|
| 5 |
Rosana M. C. Bastos, Antônio Simplício-Filho, Christian Sávio-Silva, Luiz Felipe V. Oliveira, Giuliano N. F. Cruz, Eliza H. Sousa, Irene L. Noronha, Cristóvão L. P. Mangueira, Heloísa Quaglierini-Ribeiro, Gleice R. Josefi-Rocha, Érika B. Rangel. Fecal Microbiota Transplant in a Pre-Clinical Model of Type 2 Diabetes Mellitus, Obesity and Diabetic Kidney Disease. International Journal of Molecular Sciences 2022; 23(7): 3842 doi: 10.3390/ijms23073842
|
| 6 |
Aqsa Ashfaq, Myriam Meineck, Andrea Pautz, Ebru Arioglu-Inan, Julia Weinmann-Menke, Martin C. Michel. A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy. Pharmacology & Therapeutics 2023; 249: 108503 doi: 10.1016/j.pharmthera.2023.108503
|
| 7 |
Jennifer Matthews, Lakshini Herat, Markus P. Schlaich, Vance Matthews. The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status. International Journal of Molecular Sciences 2023; 24(18): 14243 doi: 10.3390/ijms241814243
|
| 8 |
Le Deng, Yang Yang, Gaosi Xu. Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2022; 1867(12): 159234 doi: 10.1016/j.bbalip.2022.159234
|
| 9 |
Qing Fang, Na Liu, Binjie Zheng, Fei Guo, Xiangchang Zeng, Xinyi Huang, Dongsheng Ouyang. Roles of Gut Microbial Metabolites in Diabetic Kidney Disease. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.636175
|
| 10 |
Lakshini Yasaswi Herat, Jennifer Rose Matthews, Moira Hibbs, Elizabeth Piroska Rakoczy, Markus Peter Schlaich, Vance Bruce Matthews. SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes. iScience 2023; 26(8): 107260 doi: 10.1016/j.isci.2023.107260
|
| 11 |
Dalia H. El-Kashef, Haitham M. Sewilam. Empagliflozin mitigates methotrexate-induced hepatotoxicity: Targeting ASK-1/JNK/Caspase-3 pathway. International Immunopharmacology 2023; 114: 109494 doi: 10.1016/j.intimp.2022.109494
|
| 12 |
Michael Poledniczek, Christoph Neumayer, Christoph W. Kopp, Oliver Schlager, Thomas Gremmel, Alicja Jozkowicz, Michael E. Gschwandtner, Renate Koppensteiner, Patricia P. Wadowski. Micro- and Macrovascular Effects of Inflammation in Peripheral Artery Disease—Pathophysiology and Translational Therapeutic Approaches. Biomedicines 2023; 11(8): 2284 doi: 10.3390/biomedicines11082284
|
| 13 |
Omar Azzam, Vance B. Matthews, Markus P. Schlaich. Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system. Current Opinion in Nephrology & Hypertension 2022; 31(2): 135 doi: 10.1097/MNH.0000000000000767
|
| 14 |
Qinglian Hua, Yaling Han, Haifeng Zhao, Haowen Zhang, Bei Yan, Shengjie Pei, Xin He, Yue Li, Xiangyuan Meng, Lei Chen, Feng Zhong, Duo Li. Punicalagin alleviates renal injury via the gut-kidney axis in high-fat diet-induced diabetic mice. Food & Function 2022; 13(2): 867 doi: 10.1039/D1FO03343C
|
| 15 |
Rosana MC Bastos, Érika B Rangel. Gut microbiota-derived metabolites are novel targets for improving insulin resistance. World Journal of Diabetes 2022; 13(1): 65-69 doi: 10.4239/wjd.v13.i1.65
|
| 16 |
Jinghua Jiao, Honghua Yu, Litong Yao, Lihua Li, Xiaohong Yang, Lei Liu. Recent Insights into the Role of Gut Microbiota in Diabetic Retinopathy. Journal of Inflammation Research 2021; : 6929 doi: 10.2147/JIR.S336148
|
| 17 |
Yue Cai, Yongbo Kang. Gut microbiota and metabolites in diabetic retinopathy: Insights into pathogenesis for novel therapeutic strategies. Biomedicine & Pharmacotherapy 2023; 164: 114994 doi: 10.1016/j.biopha.2023.114994
|